Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Lipocine Inc. (NASDAQ:LPCN) announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late-breaking oral presentation at the EASL Congress 2024. The study showed improvements in sarcopenia and hepatic encephalopathy in patients with cirrhosis over a 52-week period.
June 10, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lipocine Inc. presented positive Phase 2 results for LPCN 1148, showing significant improvements in sarcopenia and hepatic encephalopathy in cirrhosis patients. This could boost investor confidence and positively impact the stock price in the short term.
The positive Phase 2 results for LPCN 1148, presented at a major medical conference, indicate significant clinical benefits, which are likely to boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100